Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

J&J's Ethicon buys Omrix for $438mm in cash

Executive Summary

Johnson & Johnson has agreed to acquire Israeli biomaterials and immunotherapeutics company Omrix for $25 per share (a 24% premium) in cash for each of its 17.5mm outstanding shares, for a total of $438mm or seven times its 2007 revenues of $61.7mm on earnings of $11.9mm.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Medical Devices
    • Biomaterials
    • Surgical Equipment & Devices
      • Surgical Sealants
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash

Related Companies

Advertisement
UsernamePublicRestriction

Register